Suppliers and packagers for generic pharmaceutical drug: SILDENAFIL CITRATE

SILDENAFIL CITRATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ibsa	VYBRIQUE	sildenafil citrate	FILM;ORAL	210858	NDA	IBSA Pharma Inc.	71858-0205-2	1 FILM in 1 POUCH (71858-0205-2)	2026-02-15
Ibsa	VYBRIQUE	sildenafil citrate	FILM;ORAL	210858	NDA	IBSA Pharma Inc.	71858-0205-4	1 FILM in 1 POUCH (71858-0205-4)	2026-02-15
Ibsa	VYBRIQUE	sildenafil citrate	FILM;ORAL	210858	NDA	IBSA Pharma Inc.	71858-0205-5	4 POUCH in 1 CARTON (71858-0205-5) / 1 FILM in 1 POUCH	2026-02-15

Sildenafil Citrate Suppliers: Manufacturing Landscape and Patent Analysis

Last updated: February 19, 2026

This report details the global supply chain for sildenafil citrate, a phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction and pulmonary arterial hypertension. The analysis focuses on active pharmaceutical ingredient (API) manufacturers, their production capacities, regulatory approvals, and the patent landscape surrounding the compound. Key suppliers are identified with a focus on their operational scope and market position.

What is Sildenafil Citrate?

Sildenafil citrate is a small molecule drug. It functions by increasing blood flow to specific areas of the body. The primary therapeutic applications are the treatment of erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). Its mechanism of action involves inhibiting the PDE5 enzyme, which is responsible for the breakdown of cyclic guanosine monophosphate (cGMP). Elevated cGMP levels lead to smooth muscle relaxation and vasodilation.

The molecule's chemical name is 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate. The empirical formula is C22H30N6O4S·C6H8O7, and its molecular weight is 666.7 g/mol.

Key Manufacturers of Sildenafil Citrate API

The manufacturing of sildenafil citrate API is concentrated among a limited number of global pharmaceutical ingredient producers. These companies possess the necessary chemical synthesis expertise and adhere to stringent Good Manufacturing Practice (GMP) standards required by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Manufacturer Name	Location	Primary Focus	Key Certifications	Notes
Teva Pharmaceuticals	Israel	Generic drug API production	FDA, EMA, PMDA (Japan)	One of the largest generic pharmaceutical companies globally.
Dr. Reddy's Laboratories	India	API development and manufacturing	FDA, EMA, WHO GMP	Strong portfolio in various therapeutic areas.
Aurobindo Pharma	India	API and finished dosage form manufacturing	FDA, EMA, TGA (Australia)	Significant producer of generic APIs.
Lupin Limited	India	Generic drug API and formulation manufacturing	FDA, EMA, Health Canada	Expanding global presence in generics.
Sun Pharmaceutical Industries	India	Generic and branded pharmaceutical products, API	FDA, EMA, COFEPRIS (Mexico)	Global leader in generic pharmaceuticals.
Pfizer Inc.	United States	Original innovator and manufacturer	FDA, EMA	Holds the original patents; primarily for branded products.
Shanghai Desano Chemical Technology	China	API synthesis and custom manufacturing	ISO 9001, GMP compliance (various)	Contract manufacturer with expertise in complex synthesis.
Nanjing Shengrui Biotech	China	API production	ISO 9001, GMP compliance (various)	Focus on chemical synthesis for pharmaceutical intermediates and APIs.

Production Capacity and Scale

Estimates of global sildenafil citrate API production capacity vary. However, leading Indian and Chinese manufacturers collectively account for a substantial portion of the global supply. These companies often operate multi-purpose plants capable of producing a wide range of APIs, allowing for flexibility in meeting market demand.

• India-based manufacturers are known for their cost-effective production and large-scale operations. Companies like Dr. Reddy's and Aurobindo have dedicated facilities for API synthesis, enabling them to produce hundreds of metric tons annually for various products, including sildenafil citrate.
• Chinese manufacturers, such as Shanghai Desano Chemical Technology and Nanjing Shengrui Biotech, are increasingly competitive in API production, offering both large-scale manufacturing and specialized chemical synthesis services. Their capacities are significant, contributing to global supply chain diversification.
• Pfizer, as the originator, maintains its manufacturing capabilities but its primary focus for sildenafil citrate is on its branded products. Post-patent expiry, its API production scale for the generic market is less dominant compared to specialized API manufacturers.

The total global annual production capacity for sildenafil citrate API is estimated to be in the range of 300-500 metric tons, though actual output is influenced by market demand and patent expiry timelines in various regions.

What is the Patent Landscape for Sildenafil Citrate?

The patent landscape for sildenafil citrate is characterized by expired primary patents and ongoing litigation or exploration of secondary patents.

Key Patents and Expiry Dates

The foundational patent for sildenafil citrate was filed by Pfizer.

• U.S. Patent No. 5,250,534 (claiming methods of treating sexual dysfunction and specifically the compound sildenafil) was granted on October 5, 1993. This patent expired in the United States on October 5, 2010.
• European Patent EP0463052 covering sildenafil and its use for treating erectile dysfunction expired in Europe in 2014 after extensions.

These primary patents' expiry opened the door for generic manufacturers to enter the market.

Secondary Patents and Litigation

While the compound patent has expired, pharmaceutical companies often seek to extend market exclusivity through secondary patents. These can cover:

• Formulations: Novel drug delivery systems, specific salt forms, or improved stability profiles.
• Methods of Use: New therapeutic indications or specific patient populations.
• Polymorphs: Different crystalline forms of the active ingredient that may have distinct properties.

Sildenafil citrate has been the subject of numerous patent disputes, particularly around the expiry of the primary compound patent. Generic manufacturers have challenged the validity of secondary patents, and litigation has occurred in various jurisdictions concerning the launch of generic versions.

• Formulation patents for the immediate-release tablet were a common focus. Generic companies often developed their own formulations that did not infringe on existing patents.
• Patents related to specific manufacturing processes can also exist, though these are typically harder to enforce against competitors who develop alternative synthesis routes.

Patent Expiry Impact on Market Entry

The expiry of the main sildenafil citrate patents has led to:

1. Increased Generic Competition: Numerous companies now market generic sildenafil citrate products globally. This has significantly driven down prices.
2. Market Diversification: The supply chain has expanded beyond the originator, with API manufacturers in India, China, and other regions becoming major players.
3. Focus on Niche Markets and New Indications: While the ED market is heavily commoditized, research continues for sildenafil citrate in treating other conditions, potentially leading to new patentable claims. For instance, sildenafil is approved for pulmonary arterial hypertension under different brand names (e.g., Revatio), with its own patent considerations.

Regulatory Landscape for Sildenafil Citrate API

The production and sale of sildenafil citrate API are strictly regulated by national and international health authorities. Manufacturers must comply with current Good Manufacturing Practices (cGMP) to ensure product quality, safety, and efficacy.

Key Regulatory Requirements

• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies (e.g., FDA, EMA). A DMF is a confidential submission that provides detailed information about the facilities, processes, and controls used in manufacturing, processing, packaging, and storing the API.
• Site Inspections: Manufacturing facilities are subject to regular inspections by regulatory bodies to verify compliance with cGMP. Successful inspections are crucial for market access.
• Quality Standards: APIs must meet pharmacopoeial standards, such as those outlined in the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.). These standards define acceptable limits for impurities, assay, and other quality attributes.
• Impurity Profiling: Regulatory agencies require thorough characterization and control of impurities, including genotoxic impurities. The nitrosamine impurity concern, which has affected various drug classes, has also led to increased scrutiny on sildenafil citrate manufacturing processes and impurity profiles.

Global Approvals

• U.S. Food and Drug Administration (FDA): Manufacturers seeking to supply sildenafil citrate API for the U.S. market must have their DMFs accepted by the FDA, and the API must be produced at an FDA-approved facility.
• European Medicines Agency (EMA): API suppliers for the European Union market require a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) or must have their manufacturing sites inspected and approved by national competent authorities within the EU.
• Other Agencies: Manufacturers also seek approvals from regulatory bodies in other key markets, such as Health Canada, Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and the Therapeutic Goods Administration (TGA) in Australia.

The regulatory environment for APIs is continuously evolving, with increasing emphasis on supply chain integrity, data integrity, and the control of potentially harmful impurities.

Market Dynamics and Supply Chain Considerations

The sildenafil citrate market is largely driven by the generic pharmaceutical sector. The availability of multiple API suppliers and the expiry of key patents have resulted in a competitive pricing environment.

Supply Chain Risks

• Geopolitical Factors: Reliance on APIs from specific regions can expose the supply chain to geopolitical instability, trade disputes, or unforeseen events like pandemics.
• Quality Control Issues: Any lapse in quality control by an API manufacturer can lead to product recalls, regulatory actions, and significant reputational damage for both the API supplier and the finished dosage form manufacturer.
• Raw Material Availability: The synthesis of sildenafil citrate relies on various chemical precursors. Disruptions in the supply of these raw materials can impact API production.
• Regulatory Changes: Evolving regulatory requirements, particularly concerning impurity limits and manufacturing standards, can necessitate costly process modifications for API producers.

Sourcing Strategies for Pharmaceutical Companies

Pharmaceutical companies developing or marketing sildenafil citrate finished products employ several strategies for API sourcing:

• Dual Sourcing: Establishing relationships with at least two qualified API suppliers to mitigate risk and ensure continuity of supply.
• Supplier Audits: Conducting rigorous audits of potential and existing API suppliers to assess their quality management systems, manufacturing capabilities, and regulatory compliance.
• Long-Term Contracts: Negotiating long-term supply agreements to secure pricing and ensure dedicated production capacity.
• Geographic Diversification: Sourcing APIs from manufacturers located in different geographical regions to reduce the impact of localized disruptions.

The market for sildenafil citrate API remains robust, driven by its established therapeutic role and continued demand for erectile dysfunction treatment globally. Manufacturers must navigate a complex regulatory environment and a competitive patent landscape to maintain their position.

Key Takeaways

• Sildenafil citrate API manufacturing is dominated by a few large-scale producers, primarily in India and China, alongside the originator, Pfizer.
• The expiry of primary patents for sildenafil citrate has led to widespread generic competition, significantly lowering drug prices and expanding the supplier base.
• Secondary patents and ongoing litigation focus on formulations, methods of use, and polymorphs, though their impact is diminishing as the market matures.
• Compliance with stringent cGMP standards and successful navigation of regulatory approvals (FDA, EMA, etc.) are critical for API suppliers.
• Supply chain risks include geopolitical factors, quality control failures, raw material availability, and evolving regulatory demands.
• Pharmaceutical companies typically employ dual sourcing and rigorous supplier audits to ensure a stable and compliant sildenafil citrate API supply.

Frequently Asked Questions

What is the primary reason for the concentration of sildenafil citrate API manufacturing in India and China?

The concentration is driven by cost-effectiveness in manufacturing, significant economies of scale, and established expertise in complex chemical synthesis and large-volume API production. These regions have also developed robust regulatory compliance frameworks that meet international standards.

How does the expiry of sildenafil citrate's primary patents affect the availability of the drug?

The expiry of primary patents allows multiple generic manufacturers to produce and market sildenafil citrate. This significantly increases the availability of the drug globally, often leading to lower prices due to increased competition.

What are the critical quality attributes that regulatory agencies scrutinize for sildenafil citrate API?

Regulatory agencies rigorously examine purity, including the levels of specific related substances and potential genotoxic impurities, the drug substance's assay (potency), physical characteristics like particle size distribution (if relevant for formulation), and the absence of microbial contamination. Stability data demonstrating shelf-life is also crucial.

Can sildenafil citrate API be sourced from manufacturers without FDA or EMA approval?

While it may be possible to source API from manufacturers not directly approved by the FDA or EMA, finished dosage form manufacturers who intend to market their products in the US or EU must ensure that the API is produced in facilities that meet cGMP standards and have DMFs filed and accepted by the respective regulatory bodies. Unapproved sources pose significant regulatory and quality risks.

What is the role of patent litigation in the current sildenafil citrate market?

Patent litigation in the current sildenafil citrate market primarily focuses on secondary patents, such as those covering specific formulations, methods of use, or novel crystalline forms. Litigation aims to prevent or delay generic market entry by challenging the validity of these patents or asserting their infringement. However, with the main compound patent long expired, the impact of such litigation on overall market entry is less significant than in the early post-expiry period.

Citations

[1] U.S. Patent 5,250,534. (1993). Heterocyclic compounds useful for treating sexual dysfunction. Retrieved from Google Patents. [2] European Patent EP0463052. (N.D.). Pyrazolopyrimidinones. Retrieved from Espacenet. [3] United States Pharmacopeia. (N.D.). Sildenafil Citrate Monograph. Retrieved from USP-NF Online. [4] European Pharmacopoeia. (N.D.). Sildenafil Citrate Monograph. Retrieved from Ph. Eur. Online.